China Isotope & Radiation Corporation (HKG:1763)
Hong Kong · Delayed Price · Currency is HKD 16.60
+0.18 (1.10%)
Aug 1, 2025, 4:08 PM HKT
Intra-Cellular Therapies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 7,575 | 6,635 | 6,154 | 5,144 | 4,274 | Upgrade | |
Revenue Growth (YoY) | 14.16% | 7.82% | 19.63% | 20.34% | 7.15% | Upgrade |
Cost of Revenue | 3,892 | 3,153 | 2,636 | 1,902 | 1,658 | Upgrade |
Gross Profit | 3,683 | 3,482 | 3,518 | 3,242 | 2,616 | Upgrade |
Selling, General & Admin | 2,329 | 2,406 | 2,365 | 2,320 | 1,896 | Upgrade |
Research & Development | 300.29 | 306.05 | 300.51 | 196.21 | 152.53 | Upgrade |
Other Operating Expenses | -72.24 | -50.33 | -53.81 | -28.36 | -35.17 | Upgrade |
Operating Expenses | 2,603 | 2,733 | 2,643 | 2,499 | 2,035 | Upgrade |
Operating Income | 1,080 | 749.68 | 874.88 | 742.85 | 580.55 | Upgrade |
Interest Expense | -47.21 | -34.83 | -33.66 | -34.04 | -33.2 | Upgrade |
Interest & Investment Income | 34.09 | 36.57 | 51.69 | 30.99 | 35.27 | Upgrade |
Earnings From Equity Investments | 7.27 | 16.98 | 42.17 | 60.66 | 16.37 | Upgrade |
Currency Exchange Gain (Loss) | -9.44 | -4.39 | -13.29 | -1.65 | -1.71 | Upgrade |
EBT Excluding Unusual Items | 1,065 | 764.01 | 921.78 | 798.81 | 597.28 | Upgrade |
Gain (Loss) on Sale of Investments | -19.34 | - | - | 4.55 | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.2 | 158.42 | -1.12 | -0.68 | -1.11 | Upgrade |
Other Unusual Items | 0.16 | - | 0.13 | - | - | Upgrade |
Pretax Income | 1,045 | 922.44 | 920.79 | 802.68 | 596.16 | Upgrade |
Income Tax Expense | 165.69 | 146.31 | 165.56 | 129.64 | 120.64 | Upgrade |
Earnings From Continuing Operations | 879.54 | 776.13 | 755.24 | 673.04 | 475.52 | Upgrade |
Minority Interest in Earnings | -472.89 | -405.16 | -362.96 | -337.29 | -261.94 | Upgrade |
Net Income | 406.65 | 370.97 | 392.28 | 335.75 | 213.58 | Upgrade |
Net Income to Common | 406.65 | 370.97 | 392.28 | 335.75 | 213.58 | Upgrade |
Net Income Growth | 9.62% | -5.43% | 16.84% | 57.20% | -35.09% | Upgrade |
Shares Outstanding (Basic) | 320 | 320 | 320 | 320 | 320 | Upgrade |
Shares Outstanding (Diluted) | 320 | 320 | 320 | 320 | 320 | Upgrade |
EPS (Basic) | 1.27 | 1.16 | 1.23 | 1.05 | 0.67 | Upgrade |
EPS (Diluted) | 1.27 | 1.16 | 1.23 | 1.05 | 0.67 | Upgrade |
EPS Growth | 9.62% | -5.43% | 16.84% | 57.20% | -35.09% | Upgrade |
Free Cash Flow | -889.71 | -812.66 | 286.74 | 366.59 | -118.01 | Upgrade |
Free Cash Flow Per Share | -2.78 | -2.54 | 0.90 | 1.15 | -0.37 | Upgrade |
Dividend Per Share | 0.381 | 0.313 | 0.441 | 0.378 | 0.180 | Upgrade |
Dividend Growth | 21.81% | -28.95% | 16.62% | 109.59% | 29.81% | Upgrade |
Gross Margin | 48.62% | 52.48% | 57.16% | 63.03% | 61.20% | Upgrade |
Operating Margin | 14.26% | 11.30% | 14.22% | 14.44% | 13.58% | Upgrade |
Profit Margin | 5.37% | 5.59% | 6.38% | 6.53% | 5.00% | Upgrade |
Free Cash Flow Margin | -11.75% | -12.25% | 4.66% | 7.13% | -2.76% | Upgrade |
EBITDA | 1,286 | 972.91 | 1,058 | 901.43 | 717.43 | Upgrade |
EBITDA Margin | 16.97% | 14.66% | 17.19% | 17.52% | 16.79% | Upgrade |
D&A For EBITDA | 205.76 | 223.23 | 182.76 | 158.58 | 136.88 | Upgrade |
EBIT | 1,080 | 749.68 | 874.88 | 742.85 | 580.55 | Upgrade |
EBIT Margin | 14.26% | 11.30% | 14.22% | 14.44% | 13.58% | Upgrade |
Effective Tax Rate | 15.85% | 15.86% | 17.98% | 16.15% | 20.24% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.